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FibrinogenAbstract Background: Chronic obstructive pulmonary disease (COPD) is a multicomponent
disease. There is a need for biological markers for better evaluation of patients with COPD.
Objective: To test the hypothesis that elevated levels of inﬂammatory biomarkers ﬁbrinogen,
C-reactive protein (CRP) and leukocyte count (WBC) in individuals with stable COPD are
associated with an increased risk of exacerbation.
Patients and methods: Ninety-eight COPD patients diagnosed and classiﬁed as COPD and 30
age and gender matched healthy subjects with normal pulmonary function were observed. Patient
follow-up was performed to evaluate the strength of the associations between inﬂammatory
biomarker levels and future outcome.
Results: Inﬂammatory biomarkers increase with exacerbation compared to the remission state,
mean WBC, CRP and ﬁbrinogen at 12.212 · 109/L, 39.462 mg/L and 5.09 g/L in exacerbation
respectively compared to 7.877 · 109/L, 4.142 mg/L and 2.299 g/L in remission with P values
<0.001, <0.001 and <0.004, respectively.
Statistically signiﬁcant correlation was noticed between the levels of ﬁbrinogen and the %
predicted FEV1 (r= 0.209, P= 0.038) however CRP and WBC did not correlate with % predicted
FEV1 (r= 0.031, P= 0.765) for CRP, and that for WBC (r= 0.125, P= 0.221).
Conclusion: Elevated levels of CRP, ﬁbrinogen and leukocyte count in individuals with COPD
were associated with increased exacerbation risk. Fibrinogen in particular has emerged as a
potentially useful biomarker and requires further investigation.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is amajor cause
of chronic morbidity and mortality; it is currently the fourth
highest cause of death in the world, and is predicted to be the
third leading cause of mortality worldwide by the year 2020
[1]. COPD is identiﬁedmainly according to theGlobal Initiative
800 M. Fattouh, O. AlkadyforChronicObstructiveLungDisease (GOLD) guidelines; [post
bronchodilator forced expiratory volume in 1 s (FEV1)/forced
vital capacity ratio less than 0.7; severity determined by FEV1
alone] combined with a history of exposure to risk factors [2].
There is considerable evidence of under diagnosis, especially in
the mild andmoderate groups [3]. The clinical presentation, dis-
ease severity and progression are quite heterogeneous and
maybe the result of diverse pathogenic processes that involve
abnormalities in different pathogenic pathways. Exacerbations
of respiratory symptoms in COPD are of major importance
because of their profound and long lasting adverse effects on
patients [4]. Frequent episodes accelerate loss of lung function,
affect the quality of life of patients, and are associated with poor
survival. Acute-phase proteins have been implicated in both sta-
ble and exacerbating COPD. For example, ﬁbrinogen has
emerged as a promising biomarker inCOPD. It is an acute phase
soluble plasma glycoprotein, synthesized primarily in the liver
and convertedby thrombin intoﬁbrinduringblood coagulation.
Normal ﬁbrinogen levels in blood are between 1.5 and 3.5 g/L
but can increase threefold during acute phase stimulation in
response to increased IL-6 production [5]. Elevated plasma
ﬁbrinogen has been associated with poor prognosis, especially
in a severe disease [6]. Similarly, plasma C-reactive protein
(CRP) has generally been found to be elevated in stable COPD,
althoughnot in every study; elevatedCRPwas recently shown to
increase the risk of death only in severe COPD [7]. Plasma C-
reactive protein (CRP) level has been found to be associatedwith
disease severity, quality of life, exercise capacity and response to
treatment [8]. Also; neutrophilsmay bemechanistically involved
in COPD pathology and they are elevated in the disease and
therefore make attractive biomarkers for therapeutic efﬁcacy
[9]. It was on this background that the present study was con-
ducted, which aimed to examine whether the Inﬂammatory bio-
marker tested (ﬁbrinogen, C-reactive protein (CRP) and
leukocyte count) levels in patients with stable COPDwere a sig-
niﬁcant predictor of prognosis. Also, we review the clinical evi-
dence linking themwithCOPDanddiscuss its potential utility as
a biomarker.Patients and methods
Study design and patients
This is a prospective controlled study carried out in the
Department of Chest diseases and Tuberculosis and Depart-
ment of Medical Microbiology & Immunology; Faculty of
Medicine, Sohag University during the period from January
2013 to March 2014 with a follow-up period of 12 months.
The institutional Ethics Committee approved the study.
Informed consent was obtained from patients and healthy con-
trols. Ninety eight COPD patients (Group I) were clinically
diagnosed and classiﬁed as COPD according to the medical
history, current symptoms and available pulmonary function
tests following Global Initiative for Chronic Obstructive Lung
Disease guidelines [2]. The mean age of patients including 82
males (83.7%) and 16 (16.3%) females was
62.29 ± 7.032 years. To exclude patients with asthma, subjects
with a history of allergic rhinitis or an improvement in FEV1
of >12% from the predicted values following inhalation of a
bronchodilator, were not included. Patients with evidence of
extensive pulmonary tuberculosis, malignancy or who weresuffering from psychosis were excluded from the study. All
patients with COPD were clinically stable and none had a his-
tory of respiratory infection for at least a 4-week period pre-
ceding the study. Thirty healthy individuals age- and gender-
matched with normal pulmonary function and without evi-
dence of chronic inﬂammatory disease; 23 males (76.7%) and
7 (23.3%) females have been considered as the control group
(Group II). All participants ﬁlled out a questionnaire reviewed
by an examiner at attendance, had spirometry performed, and
had blood samples analyzed.
Spirometry
Lung function data were collected using the Master Screen
PFT Erich JAEGER Spirometer, (GmbH, Wuerzburg/Ger-
many). Lung function was measured before and 15 min after
administration of 200 lg of albuterol/salbutamol. Spirometry
measures reported here include the FEV1 and FVC, as well
as the FEV1/FVC ratio. FEV1% predicted, although not
reported separately, was used to stage COPD [2]. Participants
were grouped according to Global Initiative for Chronic
Obstructive Lung Disease (GOLD) grades 1 through 4 for air-
ﬂow limitation and the recent GOLD grades A through D for
assessing both symptoms and risk. Correlations between per-
cent predicted FEV1 and each biomarker value were analyzed.
Procedures
Whole blood was collected by venipuncture into vacutainer
tubes. For serum preparation, the blood was allowed to clot
for 30 min and serum was obtained by centrifugation at
1500 rpm for 10–15 min. For plasma preparation, whole blood
was collected into vacutainer tubes containing EDTA (ethyl-
enediaminetetraacetic acid anticoagulant). Plasma was
obtained by centrifugation at 2000 rpm for 10–15 min. Serum
and plasma samples were stored at 20 C until analyzed.
Measurement of CRP levels
The measurement was done using AVITEX CRP; a rapid latex
agglutination test kit for the detection of C-reactive protein in
human serum. The AVITEX CRP latex particles are coated
with antibodies to human CRP. When the latex suspension
is mixed with serum containing elevated CRP levels on a slide,
clear agglutination is seen within 2 min. (AVITEX CRP
OMEGA DIAGNOSTICS Ltd. Omega House, Scotland, Uni-
ted Kingdom).
1. Using isotonic saline prepare serial dilutions of
patient’s serum (1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and so
on).
2. Transfer one drop (50 ll) of each serum dilution to the
test circle on the slide.
3. Shake the latex reagent, then using the dropper pro-
vided, add one drop of suspension to the test circle.
4. Mix the drops using a disposable stirrer ensuring cov-
erage of the test circle with the mixture.
5. Gently and evenly, rock and rotate the test slide for
2 min while examining the test slide for agglutination.
6. The test slide was examined under a strong light source
after 2 min. A positive result was indicated by the obvi-
ous agglutination pattern of the latex, in a clear solu-
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the latex suspension on the test slide. AVITEX CRP
has a detection limit of 6 mg/L of CRP in patient’s
serum. Positive results will be obtained at a CRP serum
concentration above 6 mg/L and negative results will
be obtained at 6 mg/L and below.
7. The serum CRP concentration can then be calculated
approximately by multiplying the dilution factor (i.e.
2, 4, 8 or 16) by the detection limit, i.e. 6, to give the
number of mg/L concentration e.g. if the agglutination
titer appears at 1/8 the approximate serum CRP con-
centration is 8 · 6 = 48 mg/L.Measurement of ﬁbrinogen levels
The measurement was done using Sysmex CA-1500 System
and the used ﬁbrinogen reagents are Multiﬁbren U (Siemens
health care diagnostic products GmbH Macburg/Germany).
Measurement of white blood cells (WBCs)
Total leukocyte count was detected by an automated method;
by using CELL-DYN 3700 (Abbott GmbH & Co. KG; Abbott
Diagnostics Europe).
Statistical analysis
Statistical differences were determined by using an analysis of
variance (ANOVA) and Student’s t-test. Results were
expressed as mean ± standard deviation of the mean (SD).
Qualitative data were compared using either Chi square test
or ﬁsher’s exact test. The probability (P value) was considered
signiﬁcant if P value was <0.05, highly signiﬁcant if P value
was <0.01 and P value< 0.001, and insigniﬁcant if P value
was > 0.05. The relationship between the studied measures
was assayed by Pearson’s linear correlation coefﬁcient. Pear-
son correlation is considered negligible if r< 0.2, weak if
between 0.2 and 0.4, moderate if between 0.4 and 0.7 and
strong if r> 0.7.Table 1 Baseline characteristics of the study participants with COP
Group
COPD Con
Gender Female 16 7
Male 82 23
Current smoker No 74 25
Yes 24 5
X smoker No 40 23
Yes 58 7
Non smoker No 82 13
Yes 16 17
Inhaled B2 agonist No 65 30
Yes 33 0
Inhaled steroid No 36 30
Yes 62 0
Theophylline No 8 30
Yes 90 0
Inhaled ipratropium No 77 30
Yes 21 0
Total 98 30
* HS, highly signiﬁcant; NS, non signiﬁcant; S, signiﬁcant.Results
The present study was carried out in the Sohag University
Hospital during the period from January 2013 to March
2014. Ninety eight COPD patients (Group I) were included
in our study in addition to 30 healthy individuals as the control
group (Group II). Baseline characteristics of the study partic-
ipants are shown in Table 1.
The relationship between the inﬂammatory biomarker levels and
disease activity: (Table 2)
Level of WBCs in the COPD patients and in the control group
The level of WBCs showed highly statistically signiﬁcant
increase in COPD patients at exacerbation (12.212 ±
6.175 · 109/L) compared to patients in remission (7.877 ±
2.118 · 109/L) (P< 0.001). Also; the level of WBCs showed
a highly statistically signiﬁcant increase in COPD patients at
exacerbation (12.212 ± 6.175 · 109/L) compared to the
control group (7.943 ± 2.295 · 109/L) (P< 0.001). (Fig. 1).
Serum level of CRP in the COPD patients and in the control
group
The serum level of CRP showed a highly statistically signiﬁ-
cant increase in COPD patients at exacerbation
(39.462 ± 65.816 mg/L) compared to patients in remission
(4.142 ± 1.134 mg/L) (P< 0.001). Also the serum level of
CRP showed a statistically signiﬁcant increase in COPD
patients at exacerbation (39.462 ± 65.816 mg/L) compared
to the control group (4.2 ± 1.11 mg/L) (P= 0.004). (Fig. 2).
Serum level of ﬁbrinogen in the COPD patients and in the
control group
The serum level of ﬁbrinogen showed a highly statistically sig-
niﬁcant increase in COPD patients at exacerbation
(5.09 ± 1.861 g/L) compared to patients in remission
(2.299 ± 0.571 g/L) (P< 0.001). Also the serum level ofD and the control group.
Total Chi square P value
trol
23 0.765 0.382 (NS)*
105
99 0.802 0.370 (NS)
29
63 11.811 <0.001 (HS)*
65
95 19.534 <0.001 (HS)
33
95 13.611 <0.001 (HS)
33
66 36.809 <0.001 (HS)
62
38 92.803 <0.001 (HS)
90
107 7.690 0.004(S)*
21
128
Table 2 The inﬂammatory biomarker levels in COPD patients at exacerbation in comparison to patients in remission and controls.
Cases at exacerbation (1) Cases at remission (2) Controls (3) P value
1 vs 2 1 vs 3 2 vs 3
FEV1 (% predicted) 53.41 ± 7.469 58.58 ± 7.927 88.4 ± 5.137 <0.001 (HS) <0.001 (HS) <0.001 (HS)
WBCs (109/L) 12.212 ± 6.175 7.877 ± 2.118 7.943 ± 2.295 <0.001 (HS) <0.001 (HS) 0.882 (NS)
CRP (mg/L) 39.462 ± 65.816 4.142 ± 1.134 4.2 ± 1.11 <0.001 (HS) 0.004 (S) 0.805 (NS)
Fibrinogen (g/L) 5.09 ± 1.861 2.299 ± 0.571 2.073 ± 0.575 <0.001 (HS) <0.001 (HS) 0.061 (NS)
Figure 1 Level of WBCs in COPD patients and in the control group.
Figure 2 Level of CRP in COPD patients and in the control group.
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COPD patients at exacerbation (5.09 ± 1.861 g/L) compared
to the control group (2.073 ± 0.575 g/L) (P< 0.001). (Fig. 3).
Correlation of the inﬂammatory biomarker levels with the lung
function decline in COPD patients
There was non-signiﬁcant correlation between the levels of
CRP and the % predicted FEV1 (r= 0.031, P= 0.765)
and there was non-signiﬁcant correlation between the leuko-
cyte count and the % predicted FEV1 (r= 0.125, P= 0.221)
while there was statistically signiﬁcant correlation betweenthe levels of ﬁbrinogen and the % predicted FEV1
(r= 0.209, P= 0.038). So ﬁbrinogen was the only inﬂamma-
tory biomarker tested associated with disease severity and can
be used as a predictor of lung function decline (Table 3).
Discussion
The global burden of COPD is large, with more than 600 mil-
lion people affected worldwide and nearly 3 million dying from
this disorder annually [10]. ‘‘Biomarkers’’ have become a hot
topic in the study and treatment of COPD. In simple terms,
a biomarker is a measurable characteristic that reﬂects the
Figure 3 Level of ﬁbrinogen in COPD patients and in the control group.
Table 3 Correlation between FEV1 and the inﬂammatory biomarker levels.
The variables At exacerbation At remission Control group
r P r P r P
WBCs 0.125 0.221 (NS) 0.179 0.077 (NS) 0.014 0.943 (NS)
CRP 0.031 0.765 (NS) 0.091 0.375 (NS) 0.132 0.485 (NS)
Fibrinogen 0.209 0.038 (S) 0.148 0.147 (NS) 0.127 0.503 (NS)
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ﬁcation in COPD is still a developing ﬁeld, with increasing
interest to aid diagnosis, deﬁne clinical phenotypes and moni-
tor response to existing and new therapeutic strategies. Fur-
thermore, blood biomarkers can be readily measured in
patients without the need for invasive procedures [5]. Agusti
et al. suggested a novel COPD phenotype characterized by per-
sistent systemic inﬂammation, based on ﬁve classic circulating
inﬂammatory biomarkers, namely CRP, IL-6, IL-8, ﬁbrinogen
and TNF-a [12]. They identiﬁed an increased risk of all-cause
mortality associated with this phenotype highlighting the role
of COPD biomarkers in clinical practice.
The present study was performed to evaluate whether levels
of CRP, ﬁbrinogen and leukocyte count; biomarkers of sys-
temic inﬂammation were signiﬁcant predictors of future
COPD outcomes. CRP was the ﬁrst biomarker to be investi-
gated in COPD. Most studies have shown that CRP levels
are elevated in these patients [8]. Liu et al. determined that a
serum CRP concentration of >3 mg/L was a poorer prognos-
tic variable of COPD compared with a CRP concentration of
63 mg/L [13]. CRP assays are inexpensive and convenient, it is
important for clinicians to use CRP values in stable COPD
patients [1]. Furthermore, ﬁbrinogen is likely to be a useful
biomarker to stratify individuals with COPD into those with
a high or low risk of future exacerbations. It is an ideal blood
biomarker for the existence of systemic inﬂammation. The lev-
els are easily measured and are already integrated into clinical
diagnostic practice. Fibrinogen has also been well studied and
associated with survival, risk of exacerbation and poor clinical
outcome [6]. In our study, levels of CRP, ﬁbrinogen and leuko-
cyte count in individuals with COPD were found to be highly
statistically signiﬁcantly higher in stable COPD patients than
in well-matched healthy control subjects and yet further rose
during exacerbations. This pattern supported the role ofinﬂammation as one driver of disease severity and a possible
protective role for elevated markers of tissue repair. Our
results that simultaneously elevated levels of CRP, ﬁbrinogen,
and leukocytes were associated with an increased risk of fre-
quent exacerbations in individuals with stable COPD were
consistent with those of previous studies, indicating the pres-
ence of systemic inﬂammation in patients with stable COPD
[14]. Also; in the present study there was a statistically signiﬁ-
cant correlation between the levels of ﬁbrinogen and the FEV1
(r= 0.209, P= 0.038). Using this FEV1-based comparator
we can develop biomarkers that better correlate with clinical
phenotypes better than FEV1. However; while the levels of
CRP and leukocyte count were also associated with disease
exacerbation they did not predict lung function decline, as
there was non-signiﬁcant correlation between the levels of
CRP (r= 0.031, P= 0.765) and the leukocyte count
(r= 0.125, P= 0.221) and FEV1. So if plasma ﬁbrinogen is
able to predict decline in FEV1 over time then it may act as
a surrogate marker of disease activity in individuals with
COPD. This would be of enormous value in our clinical setting
in which we are unable to predict those who will remain stable
and those who are likely to deteriorate rapidly. However; this
study had some limitations; we acknowledge that the selection
of biomarkers was incomplete. But the selection of the markers
in our study was based on previous studies that included a high
throughput proteomic analysis of 147 markers in stable and
unstable conditions and smoker and non-smoker controls [15].Conclusion
In conclusion, the present study conﬁrmed that there were ele-
vated levels of CRP, ﬁbrinogen and leukocyte count in individ-
uals with COPD than in healthy individuals and they were a
804 M. Fattouh, O. Alkadysigniﬁcant long-term predictor of future COPD outcomes in
individuals with airway obstruction. There was an evolving
evidence that ﬁbrinogen was a useful biomarker in COPD,
particularly in deﬁning lung function decline in COPD patients
and in acting as a surrogate marker of treatment success.
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